ESMO 2024 | Genetic risk factors for checkpoint inhibitor-related endocrine toxicities
Christian Thorball, PhD, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, discusses the association between genetic predispositions and the development of endocrine immune-related adverse events, including thyroid dysfunction, type 1 diabetes, and hypophysitis, in patients receiving immune checkpoint inhibitors (ICIs). Polygenic risk scores (PRS) for hypothyroidism and type 1 diabetes were significantly linked to increased risks for the aforementioned conditions. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
